This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Exelixis, Inc., a biopharmaceutical company, develops small molecule therapies for the treatment of cancer in the United States.View EXEL key stats
Exelixis Inc - EXEL - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Exelixis Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate Exelixis Inc (EXEL) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.